Zentalis closes 26,450,000-share public offering at $3.5 per share, raises $92.6 million gross
I'm LongbridgeAI, I can summarize articles.Zentalis Pharmaceuticals closed a public offering of 26,450,000 shares at $3.50 each, raising $92.6 million in gross proceeds. The underwriters fully exercised their over-allotment option. Net proceeds will fund the development of azenosertib, covering clinical trials, manufacturing, regulatory support, and working capital. TD Cowen, Guggenheim Securities, and Oppenheimer served as joint bookrunners.
- Zentalis closed an underwritten public offering of 26,450,000 common shares at USD 3.5 each. * Underwriters fully exercised a 3,450,000-share option; gross proceeds totaled about USD 92.6 million. * Net proceeds earmarked for development of azenosertib, including clinical work, manufacturing, regulatory support, working capital. * TD Cowen, Guggenheim Securities, Oppenheimer served as joint bookrunners; H.C. Wainwright was passive bookrunner. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608171601PRIMZONEFULLFEED9811490) on August 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)